13.JPG)
Global PARP Inhibitors Market Size is valued at USD 3.8 Billion in 2024 and is predicted to reach USD 15.5 Billion by the year 2034 at a 15.2% CAGR during the forecast period for 2025-2034.
Poly ADP-ribose polymerase or PARP inhibitor is a constituent that blocks the PARP enzyme in the cell. During cancer, DNA damage occurs. Inhibiting or blocking PARP helps the tumor cells in restoring their damaged part of DNA. Various forms of cancer are more reliant on PARP than regular cells, building PARP an attractive target for cancer treatment. PARP inhibitors seem to enhance progression-free endurance in women with recurring platinum-sensitive ovarian cancer, as shown mainly by olaparib added to conventional treatment. the growing prevalence of cancer and rising demand for effective treatment solutions are expected to boost the growth of the market substantially over the forecast period.
According to CDC estimations in 2024 about 25.4 million cases of cancer are estimated to register in the U.S. only. The growing prevalence of cancer is increasing demand for advanced treatment in the coming years. Moreover, the growing death owing to cancer, and the rising number of new cases are expected to boost the growth of market PARP inhibitors significantly.
Currently, the PARP inhibitors are approved for only a few indications including, ovarian cancer, breast cancer, prostate, and pancreatic cancer. However, various drugs are under development stages for a different indication. The presence of numerous drugs under different stages of is expected to generate immense opportunity for the PARP inhibitors market growth over the forecast period.
The growing strategic collaborations among the key players operating in the market to boost their pipeline product growth is expected to propel the market growth significantly. For instance, in January 2019, GlaxoSmithKline has acquired TESARO to expand its ovarian cancer portfolio. The acquisition allows GSK to marketing rights for Zejula (niraparib), an oral PARP inhibitor for the ovarian cancer treatment. However, the high cost of PARP inhibitors owing to the high cost of research and development activities may affect the growth of the market.
The Global PARP Inhibitors Market is segmented on the basis of product, application, and region. Based on the product, the market is segmented into Olaparib (Lynparza), Niraparib (Zejula), Talazoparib (Talzenna), Rucaparib (Rubraca), Veliparib, and Other Pipeline Drugs. In 2019, Olaparib (Lynparza) accounted for the largest share in the global PARP inhibitors market owing to its approval in major countries. Based on the application, the market is segmented into, breast cancer, ovarian cancer, and prostate and pancreatic cancer. Based on the region, the market is studied across North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Among them, North America, and Europe are estimated to account for the high share in the PARP inhibitors market globally. The increasing prevalence of sloid tumors in the regions and the presence of approved PARP inhibitors are contributing significantly to the growth of the market. Additionally, the presence of a large number of biopharmaceutical companies operating in the market and their strong pipeline are expected to propel the growth of the market over the estimated timeframe. In terms of growth rate, Asia Pacific is expected to register a high CAGR from 2023 to 2031. The growing healthcare expenditure and rising research and development activities are expected to boost the growth of the market in the Asia Pacific.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 3.8 Billion |
|
Revenue Forecast In 2034 |
USD 15.5 Billion |
|
Growth Rate CAGR |
CAGR of 15.2 % from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product and Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Johnson & Johnson Services, Inc., Merck KGaA, GSK plc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Artios Pharma, Genentech, Inc., Karyopharm Therapeutics Inc., Repare Therapeutics Inc, ONO PHARMACEUTICAL CO., LTD, Jiangsu Hengrui Pharma Co., Ltd., Bristol-Myers Squibb Co., AstraZeneca plc, Checkpoint Therapeutics, Inc., Eisai Co., Ltd., IMPACT Therapeutics, JEIL PHARMA CO.,LTD., Kyowa Kirin Co., Ltd, SyntheX. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PARP Inhibitors Market Snapshot
Chapter 4. Global PARP Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Technology Advancement in PARP Inhibitors
4.10. Key Trends in the Market
Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Niraparib (Zejula)
5.2.2. Olaparib (Lynparza)
5.2.3. Rucaparib (Rubraca)
5.2.4. Talazoparib (Talzenna)
5.2.5. Veliparib
5.2.6. Other Pipeline Drugs
Chapter 6. PARP Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis
6.1. Indication Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Ovarian Cancer
6.2.2. Breast cancer
6.2.3. Prostate and Pancreatic Cancer
Chapter 7. PARP Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by product, 2021-2034
7.1.2. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by indication, 2021-2034
7.1.3. North America PARP Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe PARP Inhibitors Market revenue (US$ Million) by product, 2021-2034
7.2.2. Europe PARP Inhibitors Market revenue (US$ Million) by indication, 2021-2034
7.2.3. Europe PARP Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by product, 2021-2034
7.3.2. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by indication, 2021-2034
7.3.3. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million)
7.4.2. Latin America PARP Inhibitors Market revenue (US$ Million) by indication, (US$ Million)
7.4.3. Latin America PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5. MEA
7.5.1. MEA revenue PARP Inhibitors Market revenue (US$ Million) by product, (US$ Million) 2021-2034
7.5.2. MEA revenue PARP Inhibitors Market revenue (US$ Million) by indication, (US$ Million) 2021-2034
7.5.3. MEA revenue PARP Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1 Johnson & Johnson Services, Inc.
8.2.2 Merck KGaA
8.2.3 GSK plc.
8.2.4 Pfizer Inc.
8.2.5 AbbVie Inc.
8.2.6 Teva Pharmaceutical Industries Ltd.
8.2.7 Artios Pharma
8.2.8 Genentech, Inc.
8.2.9 Karyopharm Therapeutics Inc.
8.2.10 Repare Therapeutics Inc
8.2.11 ONO PHARMACEUTICAL CO., LTD
8.2.12 Jiangsu Hengrui Pharma Co., Ltd.
8.2.13 Bristol-Myers Squibb Co
8.2.14 AstraZeneca plc
8.2.15 Checkpoint Therapeutics, Inc.
8.2.16 Eisai Co., Ltd.
8.2.17 IMPACT Therapeutics
8.2.18 JEIL PHARMA CO.,LTD.
8.2.19 Kyowa Kirin Co., Ltd
8.2.20 SyntheX
8.2.28. Other Prominent Players
Global PARP Inhibitors Market by Product
Global PARP Inhibitors Market by Indication
Global PARP Inhibitors Market Based on Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
